Over 1.3ML Capacity

  • Target: Pre-Clinical, Clinical & Commercial
  • Phase 1: ShenZhen Biologics I = 425,000L
  • Phase 2: Shanghai Biologics = 166,000L
  • Phase 3: ShenZhen Biologics II = 750,000L
  • Capabilities: Antibody, ADC, mRNA, vaccines, Bacteria, etc.

Collaborative Advantage

  • Cost Effective: ~60% less typical CMO (based on scale)
  • Innovative Design: Improved Samsung Design
  • Not Dependent Foreign companies: Abec, TF, Cytiva, Sartorius, etc.

Bio-CDMO sites @Cheerland